Efficacy and safety of extended-release clarithromycin (5-day short-course) vs telithromycin, in acute bacterial exacerbation of chronic bronchitis;Efficacité et tolérance de la clarithromycine, forme à libération modifiée en traitement court de cinq jours dans les exacerbations aiguës de bronchite chronique, comparativement à la télithromycine

Medecine et Maladies Infectieuses

Volumn 35, Issue 10, 2005, Pages 507-515

  Perronne, C ^a   Drugeon, H ^b   Zuck, P ^c   Filipecki, J ^d   Vincent Lacaze, N ^d   Goldfarb, G ^d   Leophonte P ^e  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c Bon Secours Hospital   (France)

^d Abbott   (France)

^e SERVICE DE PNEUMOLOGIE   (France)

Author keywords

Acute bacterial exacerbation; Chronic obstructive bronchitis; Extended release clarithromycin; Telithromycin

Indexed keywords

CLARITHROMYCIN; TELITHROMYCIN;

ABDOMINAL PAIN; ADULT; AGED; AIRFLOW; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; GASTROINTESTINAL TRACT; HAEMOPHILUS INFLUENZAE; HUMAN; MALE; MORAXELLA CATARRHALIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIAE; VOMITING;

AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KETOLIDES; MALE; MIDDLE AGED; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 28844456606     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2005.07.002     Document Type: Article

References (27)

1. G.J. Huchon, A. Vernegre, F. Neukirch, G. Brami, N. Roche, and P.-M. Preux Chronic bronchitis among French adults: high prevalence and under diagnosis Eur. Respir. J. 20 2002 806 812
2. R. Wilson, and R. Grossman The role of bacterial infection in chronic bronchitis Semin. Respir. Infect. 15 2000 1 6
3. S. Sethi Infectious exacerbations of chronic bronchitis: diagnosis and management J. Antimicrob. Chemother. 43 1999 97 105
4. R.S. Irwin, A.D. Erickson, and M.R. Pratter Prediction of tracheobronchial colonisation in current cigarette smokers with chronic obstructive bronchitis J. Infect. Dis. 145 1982 234 241
5. S.G. Adams, and A. Anzueto Antibiotic therapy in acute exacerbation of chronic bronchitis Semin. Respir. Infect. 15 2000 234 247
6. N.R. Anthonisen, J. Manfreda, C.P. Warren, E.S. Hershfield, G.K. Harding, and N.A. Nelson Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease Ann. Intern. Med. 106 1987 196 204
7. Socít́ de pneumologie de langue fraņaise (SPLF) Actualisation des recommandations pour la prise en charge de la BPCO Rev. Mal. Respir. 20 2003 4S65 4S68
8. Agence fraņaise de ścurit́ sanitaire des produits de sant́ (Afssaps) Antibioth́rapie par voie ǵńrale en pratique courante:: exacerbation de bronchite chronique Recommandations. Juillet 2001 Septembre 2002 (Actualisation)
9. P. Ĺophonte, C. Chidiac, H.B. Drugeon, S. Strabach, S. Cabrillac-Rives, and C. Chone Safran C Traitement des exacerbations de bronchopneumopathie chronique obstructive (BPCO) par la pristinamycine Rev. Mal. Respir. 21 2004 261 271
10. R. Wilson, R. Kubin, I. Ballin, K.M. Depperman, H. Bassaris, and P. Leophonte Five days moxifloxacin therapy compared with 7:days clarithromicin therapy for the treatment of exacerbations of chronic bronchitis J. Antimicrob. Chemother. 44 1999 501 513
11. H. Dabernat, M. Seguy, and C. Delmas Évaluation de l'activit́ in vitro de la t́lithromycine sur Haemophilus influenzae Pathol. Biol. 50 2002 58 62
12. H.B. Drugeon, M.E. Juvin, and A. Bensalah Épid́miologie de la ŕsistance aux antibiotiques des pathog̀nes respiratoires en France en 2000-2001:; apport de la t́lithromycine Med. Mal. Infect. 33 2003 104 109 (Moniot-Ville N et le groupe d'́tude multicentrique)
13. P. Van der Valk, E. Monninkhof, J. van der Palen, G. Zielhuis, C. van Herwaarden, and R. Hendrix Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease Clin. Infect. Dis. 39 2004 980 986
14. A. Anzueto, C.L. Fisher, T. Busman, and C.A. Olson Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbations of chronic bronchitis Clin. Ther. 23 2001 72 86
15. M. Aubier, P.M. Aldons, A. Leak, D. McKeith, B. Leroy, and M. Rangaraju Telithromycin is as effective as amoxycillin/clavulanate in acute exacerbation of chronic bronchitis Resp. Med. 96 2002 862 871
16. M.J. Zervos, A.M. Heyder, and B. Leroy Oral telithromycin 800:mg once daily for five days vs cefuroxime axetil 500:mg twice daily in adults with exacerbations of chronic bronchitis J. Internat. Med. Res. 31 2003 157 169
17. M.H. Gotfried, G. Notario, J. Spiller, R. Palmer, and T. Busman Comparative efficacy of once daily, 5:days short-course therapy with clarithromycin extended-release versus twice daily, 7:days therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis Curr. Med. Res. Opin. 21 2 2005 245 254
18. M.H. Gotfried, C.A. DeAbate, C. Fogarty, C.P. Mathew, and W.N. Sokol Comparison of 5:days, short-course gatifloxacin therapy with 7:days gatifloxacin therapy and 10:days clarithromycin therapy for acute exacerbation of chronic bronchitis Clin. Ther. 23 2001 97 107
19. S. Chodosh, C.A. DeAbate, and D. Haverstock Aneiro L and the bronchitis study group. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis Resp. Med. 94 2000 18 27
20. L.R. Weiss Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbation of chronic bronchitis Clin. Ther. 24 2002 1414 1425
21. C.A. DeAbate, D. Myers, and D. Henry Efficacy and tolerability of once-daily grepafloxacin compared with clarithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis Clin. Drug Invest. 17 1999 21 31
22. J.L. Adler, W. Janetti, D. Schneider, J. Zhang, R. Palmer, and G. Notario Phase III, randomized, double blind study of clarithromycin extended release and immediat- release formulation in the treatment of patients with acute exacerbation of chronic bronchitis Clin. Ther. 12 2000 1410 1420
23. P. Napela, Dobyniewska, T. Busman, and G. Notario Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double blind, randomized, multicenter comparison of extended release versus immediate release clarithromycin Curr. Med. Res. Opin. 19 2003 411 420
24. A. Anzueto, and S. Norris Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance Internat. J. Antimicrob. Ag. 24 2004 1 17
25. D.R.P. Guay, L. Gustavson, K.J. Devcich, J. Zhang, G. Cao, and C.A. Olson Pharmacokinetics and tolerability of extended-release clarithromycin Clin. Ther. 23 2001 566 577
26. M.J.M. Darkes, and C.M. Perry Clarithromycin extended release tablet. A review of its use in management of respiratory tract infections Am. J. Respir. Med. 32 2003 175 201
27. th European Congress of Chemotherapy and Infection (ECC), December 1-3, 2004.